Viridian Therapeutics Secures Debt Facility and Royalty Financing, Accelerates Veligrotug BLA Submission Timeline

"Viridian Therapeutics, Inc. has secured a debt facility and royalty financing agreement to support its development of treatments for serious diseases. The company has also expedited the submission timeline for its veligrotug BLA and the clinical data from its VRDN-003 trials for thyroid eye disease. Latham & Watkins LLP is advising Hercules Capital on this transaction."

Latham & Watkins LLP represented Hercules Capital in a secured debt facility upsizing and royalty financing agreement with Viridian Therapeutics, Inc. The transaction involves Hercules Capital providing a secured debt facility and entering into a royalty financing agreement with Viridian Therapeutics, which is focused on advancing its clinical timelines for the submission of the veligrotug Biologics License Application (BLA) and the topline clinical data readouts of its VRDN-003 REVEAL trials for thyroid eye disease (TED). The deal team from Latham & Watkins LLP included partners Dan Van Fleet and Haim Zaltzman, counsel Emily Yu, and associates Hyunji Lee and Scott Natsuhara. Additionally, partner Eric Cho provided advice on tax matters, while partner Eric Rice advised on convertible matters.

Viridian Therapeutics Secures Debt Facility and Royalty Financing, Accelerates Veligrotug BLA Submission Timeline

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads